Wednesday, July 8, 2026

pharma · Hereditary Angioedema · Influenza · BCRX

Biocryst

Biocryst is a pharma organization headquartered in München, DE. It trades on NYSE under ticker BCRX. Primary therapeutic focus areas include Hereditary Angioedema, Influenza, Paroxysmal Nocturnal Hemoglobinuria, Paroxysm

München, DE HQ
1986 Founded
6 Employees
Public company Type
BCRX · NYSE Ticker
Company details
Clinical program

BCX4161

Phase 3 · small molecule · Hereditary Angioedema

BCX4161 for Hereditary Angioedema is a Phase 3 program (small_molecule) at Biocryst with 4 ClinicalTrials.gov record(s).

← All Biocryst projects Phase 3 small molecule completed

Internal code BCX4161-104

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Biocryst
Phase
Phase 3
Modality
small_molecule
Indication
Hereditary Angioedema
Status
completed
Trials
4